|

Causal Effect of Coenzyme Q10 Nutrition and Cognitive Dysfunction in the Metabolic Storm (Hyperglycemia and Sarcopenia) and Brain-derived Neurotrophic Factor

RECRUITINGN/ASponsored by Chung Shan Medical University
Actively Recruiting
PhaseN/A
SponsorChung Shan Medical University
Started2023-12-26
Est. completion2026-07-31
Eligibility
Age50 Years – 80 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06040905

Summary

The aim of the study is to investigate the effect of coenzyme Q10 supplementation (150 mg/b.i.d, 300 mg/d, 12 weeks) on coenzyme Q10, glucose parameters, BDNF, myokines, and cognitive function in mild cognitive impairment (MCI) and Alzheimer's disease (AD) patients who combined with hyperglycemia but without sarcopenia, or with hyperglycemia and pre-sarcopenia.

Eligibility

Age: 50 Years – 80 YearsHealthy volunteers accepted
Inclusion Criteria:

* Clinical diagnosis of mild cognitive impairment (MCI).
* Clinical diagnosis of Alzheimer's Disease.
* MCI and AD patients with hyperglycemia ( Fasting glucose \>=100 mg/dL).
* MCI and AD patients with pre-sarcopenia (low calf circumference, low hand grip, or low muscle endurance).
* Must be able to swallow tablets.

Exclusion Criteria:

* Cancer patients.
* Severe heart, lung, liver, and kidney diseases.
* Severe disability or aphasia.
* Malnutrition (body weight changes \> 5% within one month).
* Using coenzyme Q10 supplements.
* Warfarin therapy.

Conditions5

Alzheimer DiseaseAlzheimer's DiseaseHyperglycemiaMild Cognitive ImpairmentPre-sarcopenia

Browse More Trials

Alzheimer's Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.